Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3271 ↗At a glance
Vergleichsstudie in Clinical Pharmacology & Therapeutics, 2024. Written by Raj Desai and 7 co-authors. Institution: Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA. Major MEDLINE topics: Renal Dialysis, Hematinics, Darbepoetin alfa. Cited 7 times so far (Crossref); 27 references.
Abstract (original language)
Both short‐acting (epoetin alfa or beta) and long‐acting (darbepoetin alfa or PEG‐epoetin) erythropoiesis‐stimulating agents (ESAs) are commonly prescribed for patients with kidney failure undergoing maintenance hemodialysis. We compared the risks of major adverse cardiovascular events (MACE) and of all‐cause mortality associated with receipt of short‐ vs. long‐acting ESAs. This retrospective cohort analysis included Medicare hemodialysis beneficiaries aged ≥ 18 years in the United States Renal Data System from January 2015 to December 2017. We included adults who survived > 90 days after initiating hemodialysis and received either short‐ or long‐acting ESAs. Outcomes were MACE (first occurrence of stroke, acute myocardial infarction, or cardiovascular‐related mortality) and all‐cause mortality. After stabilized inverse probability of treatment weighting, Cox proportional hazards regression models were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for each outcome. Of 68,607 patients (mean age: 65 years, 45% females), 33,658 (49%) received long‐acting ESAs and 34,949 (51%) received short‐acting ESAs. There was no difference in the risk of MACE associated with receipt of short‐ vs. long‐acting ESAs (HR: 1.02 (95% CI: 0.98–1.08)). However, long‐acting (vs. short‐acting) ESA receipt was associated with a lower risk of all‐cause mortality (HR: 0.91 (95% CI: 0.87–0.96)). Compared with short‐acting ESAs, long‐acting ESAs were associated with a lower risk of all‐cause mortality, with no difference in the risk of MACE. Future studies with a longer follow‐up are needed to confirm these findings.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
- Center for Drug Evaluation and Safety (CoDES), University of Florida, Gainesville, Florida, USA.
- College of Medicine, University of Florida, Gainesville, Florida, USA.
- North Florida South Georgia Veterans Healthcare System, Gainesville, Florida, USA.
- Division of Nephrology and Hypertension, Louisiana State University Health Sciences Center School of Medicine, New Orleans, Louisiana, USA.
- College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan, Korea.
ORCID profiles: Raj Desai, Ikenna Unigwe, Munaza Riaz, Steven M Smith, Ashutosh M Shukla, Nakyung Jeon, Haesuk Park
Cite
APA
Desai, R., Unigwe, I., Riaz, M., Smith, S. M., Shukla, A. M., Mohandas, R., Jeon, N., & Park, H. (2024). Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3271
Vancouver
Desai R, Unigwe I, Riaz M, Smith SM, Shukla AM, Mohandas R, et al. Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3271
BibTeX
@article{Desai2024,
author = {Desai, Raj and Unigwe, Ikenna and Riaz, Munaza and Smith, Steven M and Shukla, Ashutosh M and Mohandas, Rajesh and Jeon, Nakyung and Park, Haesuk},
title = {Comparative Safety of Long‐Acting vs. Short‐Acting Erythropoiesis‐Stimulating Agents Among Patients Undergoing Hemodialysis},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3271}
}
EUVIMED